Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Ritivixibat by Ipsen for Liver Diseases: Likelihood of Approval
Ritivixibat is under clinical development by Ipsen and currently in Phase I for Liver Diseases. According to GlobalData, Phase I...
Data Insights
Ritivixibat by Ipsen for Primary Sclerosing Cholangitis: Likelihood of Approval
Ritivixibat is under clinical development by Ipsen and currently in Phase II for Primary Sclerosing Cholangitis. According to GlobalData, Phase...